Real-practice management and treatment of idiopathic multicentric Castleman disease with siltuximab: a collection of clinical experiences
Castleman disease (CD) is a group of lymphoproliferative disorders that share common histopathological features yet have widely different aetiologies, clinical features and grades of severity as well as treatments and outcomes. Siltuximab is currently the only therapy approved by the FDA and EMA for...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BioExcel Publishing Ltd
2024-03-01
|
| Series: | Drugs in Context |
| Subjects: | |
| Online Access: | https://www.drugsincontext.com/real-practice-management-and-treatment-of-idiopathic-multicentric-castleman-disease-with-siltuximab-a-collection-of-clinical-experiences/ |
| _version_ | 1797265213799530496 |
|---|---|
| author | Bernardo Rossini Nicola Cecchi Felice Clemente Maria Rosaria De Paolis Stefan Hohaus Vanessa Innao Mariano Lucignano Roberto Massaiu Giovanna Palumbo Gian Matteo Rigolin Francesca Gaia Rossi Luisa Verga Attilio Guarini |
| author_facet | Bernardo Rossini Nicola Cecchi Felice Clemente Maria Rosaria De Paolis Stefan Hohaus Vanessa Innao Mariano Lucignano Roberto Massaiu Giovanna Palumbo Gian Matteo Rigolin Francesca Gaia Rossi Luisa Verga Attilio Guarini |
| author_sort | Bernardo Rossini |
| collection | DOAJ |
| description | Castleman disease (CD) is a group of lymphoproliferative disorders that share common histopathological features yet have widely different aetiologies, clinical features and grades of severity as well as treatments and outcomes. Siltuximab is currently the only therapy approved by the FDA and EMA for idiopathic multicentric CD and is recommended as first-line therapy in treatment guidelines. Despite the extensive characterization of siltuximab treatment in clinical trials, available evidence from real-world practice is still scant. This collection of clinical experiences focuses on patients treated with siltuximab therapy, particularly regarding the idiopathic multicentric CD diagnostic work-up, and on treatment administration in patients with complex disease entering differential diagnosis with CD or concomitant diseases. Thus, these data help further characterize and improve the use of siltuximab in real practice in terms of effectiveness and safety of long-term administration as well as consequences of treatment interruption. |
| first_indexed | 2024-04-25T00:41:14Z |
| format | Article |
| id | doaj.art-d8e1079613bc4dbfaebdc12a667f041e |
| institution | Directory Open Access Journal |
| issn | 1740-4398 |
| language | English |
| last_indexed | 2024-04-25T00:41:14Z |
| publishDate | 2024-03-01 |
| publisher | BioExcel Publishing Ltd |
| record_format | Article |
| series | Drugs in Context |
| spelling | doaj.art-d8e1079613bc4dbfaebdc12a667f041e2024-03-12T09:19:53ZengBioExcel Publishing LtdDrugs in Context1740-43982024-03-011311410.7573/dic.2023-9-4Real-practice management and treatment of idiopathic multicentric Castleman disease with siltuximab: a collection of clinical experiencesBernardo RossiniNicola CecchiFelice ClementeMaria Rosaria De PaolisStefan HohausVanessa InnaoMariano LucignanoRoberto MassaiuGiovanna PalumboGian Matteo RigolinFrancesca Gaia RossiLuisa VergaAttilio GuariniCastleman disease (CD) is a group of lymphoproliferative disorders that share common histopathological features yet have widely different aetiologies, clinical features and grades of severity as well as treatments and outcomes. Siltuximab is currently the only therapy approved by the FDA and EMA for idiopathic multicentric CD and is recommended as first-line therapy in treatment guidelines. Despite the extensive characterization of siltuximab treatment in clinical trials, available evidence from real-world practice is still scant. This collection of clinical experiences focuses on patients treated with siltuximab therapy, particularly regarding the idiopathic multicentric CD diagnostic work-up, and on treatment administration in patients with complex disease entering differential diagnosis with CD or concomitant diseases. Thus, these data help further characterize and improve the use of siltuximab in real practice in terms of effectiveness and safety of long-term administration as well as consequences of treatment interruption.https://www.drugsincontext.com/real-practice-management-and-treatment-of-idiopathic-multicentric-castleman-disease-with-siltuximab-a-collection-of-clinical-experiences/idiopathic multicentric castleman diseasemanagementsiltuximabtreatment |
| spellingShingle | Bernardo Rossini Nicola Cecchi Felice Clemente Maria Rosaria De Paolis Stefan Hohaus Vanessa Innao Mariano Lucignano Roberto Massaiu Giovanna Palumbo Gian Matteo Rigolin Francesca Gaia Rossi Luisa Verga Attilio Guarini Real-practice management and treatment of idiopathic multicentric Castleman disease with siltuximab: a collection of clinical experiences Drugs in Context idiopathic multicentric castleman disease management siltuximab treatment |
| title | Real-practice management and treatment of idiopathic multicentric Castleman disease with siltuximab: a collection of clinical experiences |
| title_full | Real-practice management and treatment of idiopathic multicentric Castleman disease with siltuximab: a collection of clinical experiences |
| title_fullStr | Real-practice management and treatment of idiopathic multicentric Castleman disease with siltuximab: a collection of clinical experiences |
| title_full_unstemmed | Real-practice management and treatment of idiopathic multicentric Castleman disease with siltuximab: a collection of clinical experiences |
| title_short | Real-practice management and treatment of idiopathic multicentric Castleman disease with siltuximab: a collection of clinical experiences |
| title_sort | real practice management and treatment of idiopathic multicentric castleman disease with siltuximab a collection of clinical experiences |
| topic | idiopathic multicentric castleman disease management siltuximab treatment |
| url | https://www.drugsincontext.com/real-practice-management-and-treatment-of-idiopathic-multicentric-castleman-disease-with-siltuximab-a-collection-of-clinical-experiences/ |
| work_keys_str_mv | AT bernardorossini realpracticemanagementandtreatmentofidiopathicmulticentriccastlemandiseasewithsiltuximabacollectionofclinicalexperiences AT nicolacecchi realpracticemanagementandtreatmentofidiopathicmulticentriccastlemandiseasewithsiltuximabacollectionofclinicalexperiences AT feliceclemente realpracticemanagementandtreatmentofidiopathicmulticentriccastlemandiseasewithsiltuximabacollectionofclinicalexperiences AT mariarosariadepaolis realpracticemanagementandtreatmentofidiopathicmulticentriccastlemandiseasewithsiltuximabacollectionofclinicalexperiences AT stefanhohaus realpracticemanagementandtreatmentofidiopathicmulticentriccastlemandiseasewithsiltuximabacollectionofclinicalexperiences AT vanessainnao realpracticemanagementandtreatmentofidiopathicmulticentriccastlemandiseasewithsiltuximabacollectionofclinicalexperiences AT marianolucignano realpracticemanagementandtreatmentofidiopathicmulticentriccastlemandiseasewithsiltuximabacollectionofclinicalexperiences AT robertomassaiu realpracticemanagementandtreatmentofidiopathicmulticentriccastlemandiseasewithsiltuximabacollectionofclinicalexperiences AT giovannapalumbo realpracticemanagementandtreatmentofidiopathicmulticentriccastlemandiseasewithsiltuximabacollectionofclinicalexperiences AT gianmatteorigolin realpracticemanagementandtreatmentofidiopathicmulticentriccastlemandiseasewithsiltuximabacollectionofclinicalexperiences AT francescagaiarossi realpracticemanagementandtreatmentofidiopathicmulticentriccastlemandiseasewithsiltuximabacollectionofclinicalexperiences AT luisaverga realpracticemanagementandtreatmentofidiopathicmulticentriccastlemandiseasewithsiltuximabacollectionofclinicalexperiences AT attilioguarini realpracticemanagementandtreatmentofidiopathicmulticentriccastlemandiseasewithsiltuximabacollectionofclinicalexperiences |